ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,632.33
1.05%
Dow Jones
41,488.19
1.65%
Gold vs US Dollar
2,986.65
0.00%
Brent Oil
70.285
0.00%
Bitcoin
84,270.40
0.37%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Phaxiam Therapeutics (0QSS)

  7. Phaxiam Therapeutics (0QSS) News

Phaxiam Therapeutics (0QSS)

Phaxiam Therapeutics
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0QSS
DateTimeSourceHeadlineSymbolCompany
05/12/202417:00UK RegulatoryPHAXIAM Therapeutics : information mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 novembre 2024LSE:0QSSPhaxiam Therapeutics
05/12/202417:00UK RegulatoryPHAXIAM Therapeutics : monthly information related to total number of voting rights and shares composing the share capital – November 29, 2024LSE:0QSSPhaxiam Therapeutics
27/11/202413:30UK RegulatoryPHAXIAM présente une stratégie de développement ambitieuse pour tirer parti de l'évolution rapide du marché de la phagothérapieLSE:0QSSPhaxiam Therapeutics
27/11/202413:30UK RegulatoryPHAXIAM Therapeutics presents an ambitious development strategy to take advantage of the rapidly evolving Phages therapy areaLSE:0QSSPhaxiam Therapeutics
18/11/202417:00UK RegulatoryPHAXIAM a présenté son test IVD Phagogramme et l’actualisation du suivi de sensibilité à ses phages lors du premier « Phagogram Day »LSE:0QSSPhaxiam Therapeutics
18/11/202417:00UK RegulatoryPHAXIAM Presented its IVD Phagogram test and updated phage susceptibility tracking at the first "Phagogram Day"LSE:0QSSPhaxiam Therapeutics
13/11/202416:45UK RegulatoryPHAXIAM publie l’information financière du troisième trimestre 2024LSE:0QSSPhaxiam Therapeutics
13/11/202416:45UK RegulatoryPHAXIAM Reports Third-Quarter 2024 Financial InformationLSE:0QSSPhaxiam Therapeutics
08/11/202417:00UK RegulatoryInformation mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2024LSE:0QSSPhaxiam Therapeutics
08/11/202417:00UK RegulatoryMonthly information related to total number of voting rights and shares composing the share capital – October 31, 2024LSE:0QSSPhaxiam Therapeutics
04/11/202417:00UK RegulatoryPHAXIAM Therapeutics obtient l’autorisation de la FDA américaine pour lancer l’étude de phase II GLORIA aux Etats-UnisLSE:0QSSPhaxiam Therapeutics
04/11/202417:00UK RegulatoryPHAXIAM Therapeutics Receives FDA Clearance to Initiate Phase II GLORIA Study in the U.S.LSE:0QSSPhaxiam Therapeutics
10/10/202416:00UK RegulatoryMonthly information related to total number of voting rights and shares composing the share capital – October 8, 2024LSE:0QSSPhaxiam Therapeutics
10/10/202416:00UK RegulatoryInformation mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 8 octobre 2024LSE:0QSSPhaxiam Therapeutics
09/10/202416:00UK RegulatoryPHAXIAM Therapeutics annonce la validation d’une nouvelle étude de phase 2, PHAGOSCARPA, sponsorisée par un investigateurLSE:0QSSPhaxiam Therapeutics
09/10/202416:00UK RegulatoryPHAXIAM Therapeutics announces the validation of a new investigator-initiated phase 2 studyLSE:0QSSPhaxiam Therapeutics
25/09/202415:45UK RegulatoryPHAXIAM Provides Business and Financial Update For the First Half of 2024LSE:0QSSPhaxiam Therapeutics
25/09/202415:45UK RegulatoryPHAXIAM fait le point sur ses activités et publie ses résultats financiers du premier semestre 2024LSE:0QSSPhaxiam Therapeutics
25/09/202415:45UK RegulatoryPHAXIAM : RAPPORT FINANCIER SEMESTRIELLSE:0QSSPhaxiam Therapeutics
20/03/202417:00UK RegulatoryPHAXIAM Therapeutics publie ses résultats annuels 2023 et fait le point sur ses activitésLSE:0QSSPhaxiam Therapeutics
20/03/202417:00UK RegulatoryPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateLSE:0QSSPhaxiam Therapeutics
11/03/202406:00UK RegulatoryPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketLSE:0QSSPhaxiam Therapeutics
11/03/202406:00UK RegulatoryPHAXIAM Therapeutics annonce la réalisation du retrait volontaire de ses « American Depository Shares » du Nasdaq Stock MarketLSE:0QSSPhaxiam Therapeutics
05/03/202417:00UK RegulatoryMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024LSE:0QSSPhaxiam Therapeutics
05/03/202417:00UK RegulatoryInformation mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 29 février 2024LSE:0QSSPhaxiam Therapeutics
20/02/202421:05UK RegulatoryPHAXIAM Therapeutics annonce son intention de procéder au retrait volontaire de ses « American Depositary Shares » du Nasdaq Capital MarketLSE:0QSSPhaxiam Therapeutics
20/02/202421:05UK RegulatoryPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketLSE:0QSSPhaxiam Therapeutics
06/02/202421:05UK RegulatoryMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024LSE:0QSSPhaxiam Therapeutics
06/02/202421:05UK RegulatoryInformation mensuelle relative au nombre total de droits de vote et d’actions composant le capital social au 31 janvier 2024LSE:0QSSPhaxiam Therapeutics
 Showing the most relevant articles for your search:LSE:0QSS

Your Recent History

LSE
SBTX
Skinbiotherapeutics
LSE
VAST
Vast Resources
LSE
PHE
Powerhouse Energy
LSE
AAZ
Anglo Asian Mining
LSE
AGL
Angle
LSE
GKP
Gulf Keystone Petroleum
LSE
WG.
Wood Group (john)
LSE
GFM
Griffin Mining
LSE
GOLD
LSE
SYME
Supply@me Capital
LSE
BARC
Barclays
LSE
ITV
Itv
LSE
SRSP
Sirius Petroleum
LSE
MIN
Minoan
LSE
AXL
Arrow Exploration
LSE
RKH
Rockhopper Exploration
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads